Disruption of p53 in Human Cancer Cells Alters the Responses to Therapeutic Agents

Case ID:
C03920
C03920: Disruption of p53 in Human Cancer Cells Alters the Responses to Therapeutic Agents
Technical Details:
p53 knockout in human colorectal cancer cell line HCT116. Details are described in the paper by Bunz et al., 1999
Looking for Partners:
The p53 gene is inactivated in the majority of human cancers. JHU scientists determined that p53 knockout cell lines have altered responses to therapeutic agents, being sensitized to DNA damaging agents but resistant to anti-metabolite 5-fluorouracil. This novel knock-out line provides the basis for a new drug screen to identify compounds that specifically kill cells with p53 mutations.

 
Patent Information:
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum